SCG142
Phase 2Biologic
SCG142 is one of 14 biologic programs targeting Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Carcinoma
#DrugCompanyPhaseTrials
1Afinitor
NovartisPhase 3
Fludara
SanofiPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Klisyri
AAlmirall, S.A.
Phase 2
TQB3454
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
SCG142
SSCG Cell Therapy Pte. Ltd.
Phase 2
Administration of AVP
AAssistance Publique - Hôpitaux de Paris
Preclinical
SZ011 CAR-NK
SShantou University Medical College
Phase 1
Ga-NOTA-T4
RRenJi Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCG142. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- SSCG Cell Therapy Pte. Ltd.